Filing Flows › Relay Therapeutics (RLAY) › Q2 2026
Relay Therapeutics (RLAY) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Relay Therapeutics (RLAY) reported revenue of $350K for the second quarter 2026 (Q2 2026), -48% from a year earlier and -88% from the quarter before.
Relay Therapeutics, Q2 2026: revenue $350K (-48% year over year), net loss $83.7M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $350K | -88% | -48% |
| Operating profit | −$90.8M | — | — |
| Net earnings | −$83.7M | — | — |
| Operating cash flow | −$54.1M | — | — |
What changed
Revenue was $350K in Q2 2026, down 48% year over year and down 88% from the previous quarter.
Operating costs exceeded revenue by $90.8M, an operating margin of -25949.7%. Total costs grew 18% against a revenue fall of 48%. The fastest-growing cost line was Research & development (+20%). The quarter ended with a net loss of $83.7M, wider than the previous quarter's $73.3M loss.
Operating cash flow was −$54.1M. Non-cash charges added back $360K of depreciation and $9.2M of share-based compensation. Working capital and other items added $20.1M.
Questions
What was Relay Therapeutics' revenue in the second quarter 2026?
Relay Therapeutics (RLAY) reported revenue of $350K for the second quarter 2026 (Q2 2026), -48% from a year earlier and -88% from the quarter before.
Source: Relay Therapeutics 10-Q on SEC EDGAR.